A Study to Assess the Added Value of CTA in the Algorithm for Management of Acute Lower GI Bleeding

Overview

About this study

The purpose of this study is to determine the value of CTA as a first-line diagnostic study in hemodynamically stable patients who present to the emergency room with signs of lower GI bleeding that will undergo colonoscopy with bowel preparation.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Signs of lower GI bleeding with either maroon or melenotic stools (and negative EGD in the last month) or hematochezia.
Plan for admission and colonoscopy.
Patients 40 years of age or older.

Exclusion Criteria:

Impaired renal function with a GFR less than 30.
Pregnancy.A urine pregnancy test will be performed in women who have the potential of pregnancy.
History of a severe iodinated contrast allergy. A history of a few hives will not be an exclusion.
Those with suspected post-polypectomy bleeding.
Suspected bleeding from hemorrhoid or anal fissure on physical exam.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Jeff Fidler, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Jeff Fidler, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials